[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335880-105":59,"doc-detail-335880-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","new-ceacam-targeting-2a3-single-domain-antibody-based-chimeric-antigen-receptor-t-cells-produce-anticancer-effects-in-vitro-and-in-vivo","New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo","","Breakthrough CAR T-cell immunotherapy for hematooncology requires tumor-specific molecular targets for solid cancers. CEACAM family proteins are implicated in malignancies and represent attractive anticancer targets. This study evaluates newly engineered CEACAM-targeted 2A3 single-domain antibody-based CAR T-cells for antitumor activity in vitro and in animal models. Co-incubation indicates cross-reactivity, with 2A3-CAR T-cells activated and highly cytotoxic against CEACAM5 and/or CEACAM6 high cell lines, and in vivo efficacy in BxPC-3 pancreatic cancer xenografts across early and late interventions. Results support further development against CEACAM5/6-overexpressing cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/new-ceacam-targeting-2a3-single-domain-antibody-based-chimeric-antigen-receptor-t-cells-produce-anticancer-effects-in-vitro-and-in-vivo/335880/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/new-ceacam-targeting-2a3-single-domain-antibody-based-chimeric-antigen-receptor-t-cells-produce-anticancer-effects-in-vitro-and-in-vivo/335880.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address for applying CAR T-cell therapy to solid cancers?","Question",{"text":112,"@type":113},"Solid tumors require suitable molecular targets to make CAR T-cell treatment effective. The study focuses on identifying CEACAM family proteins as such targets and testing a new CEACAM-targeting CAR T-cell construct.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the 2A3 sdAb CAR T-cell show activity against CEACAM5 and CEACAM6?",{"text":117,"@type":113},"In vitro co-incubation experiments showed activation and high cytotoxicity of 2A3-CAR T-cells against CEACAM5 and/or CEACAM6 high human cell lines, indicating cross-reactivity beyond the initially reported CEACAM6 target.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the antitumor effect of 2A3-CAR T-cells in vivo?",{"text":121,"@type":113},"In the BxPC-3 pancreatic cancer xenograft model, 2A3-CAR T-cells demonstrated high efficacy against pancreatic cancer xenografts in both early and late intervention regimens.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335880,1790085328,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Cancer Immunology, Immunotherapy (2024) 73:30 [https://doi.org/10.1007/s00262-023-03602-4](https://doi.org/10.1007/s00262-023-03602-4)  \nNew CEACAM‑targeting 2A3 single‑domain antibody‑based chimeric antigen receptor T‑cells produce anticancer effects in vitro and in vivo  \nIga Jancewicz1 · Magdalena Śmiech1 · Magdalena Winiarska1,2 · Radoslaw Zagozdzon1,3,4 · Pawel Wisniewski1  \nReceived: 29 August 2023 / Accepted: 20 November 2023 / Published online: 27 January 2024 © The Author(s) 2024  \nAbstract  \nRecently, a breakthrough immunotherapeutic strategy of chimeric antigen receptor (CAR) T-cells has been introduced to hematooncology. However, to apply this novel treatment in solid cancers, one must identify suitable molecular targets in the tumors of choice. CEACAM family proteins are involved in the progression of a range of malignancies, including pancreatic and breast cancers, and pose attractive targets for anticancer therapies. In this work, we used a new CEACAM-targeted 2A3 single-domain antibody-based chimeric antigen receptor T-cells to evaluate their antitumor properties in vitro and in animal models. Originally, 2A3 antibody was reported to target CEACAM6 molecule; however, our in vitro co-incubation experiments showed activation and high cytotoxicity of 2A3-CAR T-cells against CEACAM5 and/or CEACAM6 high human cell lines, suggesting cross-reactivity of this antibody. Moreover, 2A3-CAR T-cells tested in vivo in the BxPC-3 xenograft model demonstrated high efficacy against pancreatic cancer xenografts in both early and late intervention treatment regimens. Our results for the first time show an enhanced targeting toward CEACAM5 and CEACAM6 molecules by the new 2A3 sdAb-based CAR T-cells. The results strongly support the further development of 2A3-CAR T-cells as a potential treatment strategy against CEACAM5/6-overexpressing cancers.  \nKeywords Nanobodies · Cancer microenvironment · Immune checkpoints · Cancer biomarker · CEACAM5/6 · CART-cells  \nIntroduction  \nFollowing successes in difficult-to-treat diseases such as malignant melanoma and lung cancer, checkpoint-targeted immunotherapy has been attempted in a range of solid cancers, including pancreatic ductal adenocarcinoma (PDAC)  \n[1], refractory estrogen receptor (ER)-positive [2] and  \nIga Jancewicz and Magdalena Śmiech have equally contributed to this study.  \n* Radoslaw Zagozdzon [radoslaw.zagozdzon@wum.edu.pl](radoslaw.zagozdzon@wum.edu.pl)  \n* Pawel Wisniewski [p.wisniewski@4celltherapies.com](p.wisniewski@4celltherapies.com)  \nIga Jancewicz[i.jancewicz@4celltherapies.com](i.jancewicz@4celltherapies.com)[ ](i.jancewicz@4celltherapies.com)Magdalena Śmiech  \n[m.smiech@4celltherapies.com](m.smiech@4celltherapies.com)[ ](m.smiech@4celltherapies.com)Magdalena Winiarska [magdawiniarska@gmail.com](magdawiniarska@gmail.com)  \nhuman epidermal growth factor receptor 2 (HER2)-positive breast cancers [2, 3] . Unfortunately, single-agent targeting of the classical immune checkpoints such as cytotoxic T-cell antigen 4 (CTLA-4) or the programmed death-receptor 1 (PD-1)/PD-L1 axis has produced little to no benefit for pancreatic cancer patients or endocrine-resistant breast cancer [2] and has been only moderately improved by combination approaches [1]. Nevertheless, multiple lines of evidence suggest that these malignancies occur in an immunosuppressive  \n1 4Cell Therapies S.A., 59C Bojkowska Street, 44-100 Gliwice, Poland  \n2 Department of Immunology, Medical University of Warsaw, 5 Nielubowicza St., Building F, 02-097 Warsaw, Poland  \n3 Laboratory of Cellular and Genetic Therapies, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland  \n4 Department of Regenerative Medicine, The Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland  \nmicroenvironment [4], which is an obstacle to immunotherapeutic approaches [5] . Possibly, alternative immune checkpoints play an immunosuppressive role in these cancers. Among othe","cbCailKv2oyokas5","https://ap.wps.com/l/cbCailKv2oyokas5","pdf",2035319,13,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What problem does the study address for applying CAR T-cell therapy to solid cancers?\",\"answer\":\"Solid tumors require suitable molecular targets to make CAR T-cell treatment effective. The study focuses on identifying CEACAM family proteins as such targets and testing a new CEACAM-targeting CAR T-cell construct.\"},{\"question\":\"How does the 2A3 sdAb CAR T-cell show activity against CEACAM5 and CEACAM6?\",\"answer\":\"In vitro co-incubation experiments showed activation and high cytotoxicity of 2A3-CAR T-cells against CEACAM5 and/or CEACAM6 high human cell lines, indicating cross-reactivity beyond the initially reported CEACAM6 target.\"},{\"question\":\"What evidence supports the antitumor effect of 2A3-CAR T-cells in vivo?\",\"answer\":\"In the BxPC-3 pancreatic cancer xenograft model, 2A3-CAR T-cells demonstrated high efficacy against pancreatic cancer xenografts in both early and late intervention regimens.\"}]","New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo | PDF",1790012675,33]